Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002971 · ClinicalTrials.gov registry record · Phase 1
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002971: Completed Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT00002971 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002971, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery to patients who have malignant glioma.
Interventions
- DRUG O6-benzylguanine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-06-19 |
| Est. Completion | 2009-01-01 |
| Phase | Phase 1 |
What the finished NCT00002971 record still lists
NCT00002971 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which O6-benzylguanine is the first listed.
NCT00002971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002971 about?
NCT00002971 is a clinical study titled "O(6)-Benzylguanine in Treating Patients With Malignant Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery to patients who have malignant glioma.
What is the current status of trial NCT00002971?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-06-19. Estimated completion is 2009-01-01.
What interventions are being tested in trial NCT00002971?
The interventions under investigation include: O6-benzylguanine (DRUG).
Who is sponsoring clinical trial NCT00002971?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI